VPTD.F Stock Overview
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
VentriPoint Diagnostics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.16 |
| 52 Week High | CA$0.27 |
| 52 Week Low | CA$0.092 |
| Beta | 0.40 |
| 1 Month Change | -9.30% |
| 3 Month Change | -26.07% |
| 1 Year Change | 45.36% |
| 3 Year Change | -63.59% |
| 5 Year Change | 127.13% |
| Change since IPO | -92.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| VPTD.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.1% | 1.8% | 1.2% |
| 1Y | 45.4% | -0.5% | 24.9% |
Return vs Industry: VPTD.F exceeded the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: VPTD.F exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| VPTD.F volatility | |
|---|---|
| VPTD.F Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VPTD.F's share price has been volatile over the past 3 months.
Volatility Over Time: VPTD.F's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Hugh MacNaught | www.ventripoint.com |
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity of chemotherapy treatments for cancer, and Covid-19 related heart issues.
VentriPoint Diagnostics Ltd. Fundamentals Summary
| VPTD.F fundamental statistics | |
|---|---|
| Market cap | US$25.24m |
| Earnings (TTM) | -US$3.46m |
| Revenue (TTM) | US$26.19k |
919.8x
P/S Ratio-7.0x
P/E RatioIs VPTD.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VPTD.F income statement (TTM) | |
|---|---|
| Revenue | CA$35.89k |
| Cost of Revenue | CA$12.61k |
| Gross Profit | CA$23.28k |
| Other Expenses | CA$4.76m |
| Earnings | -CA$4.74m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 64.86% |
| Net Profit Margin | -13,205.39% |
| Debt/Equity Ratio | 10.8% |
How did VPTD.F perform over the long term?
See historical performance and comparison